News and Comments


  Wednesday, April 28, 2010

Despite the emergence of new biological treatments for cancer, Chemotherapy is still essential, and indispensable as a major treatment for malignancies. The adverse events caused by these chemicals were found to be acceptable as a risk versus the great reward of using chemotherapy. The technological evolution that took place in the past decade and the surfacing of state-of-the-art technologies such as nanotechnology, scientists believed possibilities exist now for improving the adverse effect profiles of these therapeutic molecules. Reformulating the existing products has become an increasingly common product lifecycle-management technique. We read that a 2004 report on the U.S. drug market from BCC, Inc. projected that reformulations would grow from 62% of the market in 2003 to 79% in 2008. Finding ways to modify and improve existing products’ side effect profiles has become feasible after being essential but unreachable goal.  More...

Recent Postings



Illumina (ILMN) Human Longevity (HLI) Onyx (ONXX) Velcade (bortezomib) NEKTAR (NKTR)) ZALTRAP™ GlaxoSmithKline (GSK) Multiple Myeloma Merck (MRK) Trastuzumab-DM1 Ionis (IONS) Cytokinetics (CYTK) SERES THERAPEUTICS (MCRB) Valeant Pharmaceuticals International (VRX) AstraZeneca (AZN) Zerenex REGULUS (RGLS) Agenus (AGEN) Aimmune Therapeutics (AIMT) Dendreon (DNDN) KERYX (KERX) Mirati Therapeutics (MRTX) Ziofpharm (ZIOP) Roche (ROCHE) Idenix (IDIX) INNOVIVA (INVA) Bristol-Myers Squibb (BMY) Theravance Bio Pharma (TBPH) Human Genome Sciences (HGSI) Exelixis (EXEL) Gilead (GILD) ADVENTRIX (ANX) Global Cell Therapeutics (GBT) Amgen (AMGN) RenenxBio (RGNX) Theravance (THRX) Seattle Genetics (SGEN) Intermune (ITMN) ABBVIE (ABBV) Auspex (ASPX) Sarepta (SRPT) Incyte (INCY) KITE (KITE) Anacor (ANAC) JUNO (JUNO) Revlimid (lenolidamide) Roche (RHHBY) Sequenom (SQNM) Herceptin Intrexon (XON) Sanofi (SNY) CompuGen (CGEN) ACADIA (ACAD) NOVOCURE (NVCR) Jazz Pharmaceuticals (JAZZ) Array Pharmaceuticals (ARRY) ARCA (ABIO) Sanofi (SNA) MODERNA Spike Therapeutics (ONCE) Dynavax (DVAX) Pluristem (PSTI) Xoma (XOMA) GUARDIAN HEALTH Editas (EDIT) Biogen Idec (BIIB) Prosensa (RNA) Vitae Pharmaceuticals (VTAE) SYNTA (SNTA) AGOS (ARGS) SUNESIS PHARMACEUTICALS (SNSS) Abbott Laboratories (ABT) Tysabri Prolor Biotech (PBTH) ISIS (ISIS) Galena (GALE) Ariad (ARIA) Regeneron (REGN) Biocryst (BCRX) Sanofi-Aventis (SAN) Alder Biopharmaceuticals (ALDR) Benlysta (belimumab) VANDA (VNDA) Sangamo (SGMO) galapagos (GLPG) Telaprevir BIOMARIN (BMRN) IDERA (IDRA) Vertex (VRTX) Endometrial Cancer C4 Therapeutics Agenus (AGEN Intercept (ICPT) Rapamune OSI (OSIP) Inovio (INO) ARGOS (ARGS) Anadys (ANDS) Elan (ELN) PTC Therapeutics (PTCT) Micromet (MITI) TOKAI (TKAOI) HALOZYME (HALO) Alnylam (ALNY) Genentech AERIE PHARMACEUTICALS NANTKWEST (NK) ImmunoGen (IMGN) Ridaforolimus